Eczema Newswire (Page 7)

Eczema Newswire (Page 7)

Comprehensive Real-Time News Feed for Eczema. (Page 7)

Results 121 - 140 of 498 in Eczema

  1. Researchers reveal allergies may be linked to eczemaRead the original story w/Photo

    May 6, 2017 | NewsTarget.com

    Researchers infer that allergy and eczema may go hand in hand, and stress that understanding the connection between the two conditions may mitigate the risk of suffering from the latter. "It is important for both patients and healthcare professionals to understand the connection between atopic eczema and allergy.

    Comment?

  2. Eczema Treatment Market Research Report - Future Demand and Growth Analysis with Forecast 2025Read the original story w/Photo

    May 5, 2017 | SBWire

    Eczema, also referred as dermatitis or atopic dermatitis, is a disease which results in inflammation of the skin. Eczema is characterized by rash, red skin, and itchiness.

    Comment?

  3. British stocks lag Europe as miners, retailer Next sinkRead the original story w/Photo

    May 4, 2017 | Reuters

    ... industry consolidation paragraph 13, updates stock prices, paragraph 5) May 4 Regeneron Pharmaceuticals Inc said its eczema drug Dupixent was off to a strong start and the biotech stood by its full-year sales forecast for its flagship drug Eylea ...

    Comment?

  4. UPDATE 4-As Eylea fears fade, focus turns to Regeneron's eczema drugRead the original story w/Photo

    May 4, 2017 | Reuters

    ) said its eczema drug Dupixent was off to a strong start and the biotech stood by its full-year sales forecast for its flagship drug Eylea even as competition heats up. Regeneron is betting on two key treatments - sarilumab, to treat rheumatoid ...

    Comment?

  5. UPDATE 3-As Eylea fears fade, focus turns to Regeneron's eczema drugRead the original story w/Photo

    May 4, 2017 | Reuters

    May 4 Regeneron Pharmaceuticals Inc stood by its full-year sales forecast for its flagship drug Eylea and said the early adoption of its eczema drug Dupixent was encouraging, easing concerns about the company's reliance on Eylea as competition heats up. Regeneron's shares jumped nearly 6 percent to $430.93 on Thursday, rising for the fifth day in a row to touch levels last seen in November.

    Comment?

  6. BRIEF-Interactive Entertainment China Cultural Technology Investments says unit entered into SPARead the original story w/Photo

    May 4, 2017 | Reuters

    ... Inc stood by its full-year sales forecast for its flagship drug Eylea and said the early adoption of its eczema drug Dupixent was encouraging, easing concerns about the company's reliance on Eylea as competition heats up. DAKAR, May 4 (Thomson ...

    Comment?

  7. BRIEF-Deva Holding Q1 net profit rises to 20.9 million liraRead the original story w/Photo

    May 4, 2017 | Reuters

    May 4 Regeneron Pharmaceuticals Inc stood by its full-year sales forecast for its flagship drug Eylea and said the early adoption of its eczema drug Dupixent was encouraging, easing concerns about the company's reliance on Eylea as competition heats up.

    Comment?

  8. BRIEF-Time Inc says Essence Brand partnering with Twitter to livestream "Essence Now"Read the original story w/Photo

    May 4, 2017 | Reuters

    May 4 Regeneron Pharmaceuticals Inc stood by its full-year sales forecast for its flagship drug Eylea and said the early adoption of its eczema drug Dupixent was encouraging, easing concerns about the company's reliance on Eylea as competition heats up.

    Comment?

  9. METALS-Copper slides to five-month lows as inventories surgeRead the original story w/Photo

    May 4, 2017 | Reuters

    ... rmaceuticals Inc stood by its full-year sales forecast for its flagship drug Eylea and said the early adoption of its eczema drug Dupixent was encouraging, easing concerns about the company's reliance on Eylea as competition heats up.

    Comment?

  10. Regeneron confident despite lackluster Q1 earningsRead the original story w/Photo

    May 4, 2017 | Albany Times Union

    ... first quarter earnings estimates. But things still look bright for the company, which is currently sitting on a new eczema treatment that market analysts believe could be worth billions of dollars. Shares in Regeneron (Nasdaq: REGN) were down 1 ...

    Comment?

  11. I Thought I was Damaged GoodsRead the original story w/Photo

    May 3, 2017 | Psychology Today

    ... upper lip is dark and scaly all the more jarring. There's not much question about what she has: atopic dermatitis, or eczema. That much you can see from across the room. The question is why she isn't treating this more effectively, since treating ...

    Comment?

  12. 3 Key Things to Watch in Pfizer's Q1 ResultsRead the original story

    Apr 30, 2017 | Fox News

    ... The lead product obtained from the Anacor buyout, Eucrisa, won U.S. regulatory approval in December for treating eczema. When Pfizer acquired Anacor, it expressed confidence that Eucrisa (then known as crisaberole) would achieve peak annual sales of ...

    Comment?

  13. Is Regeneron (Finally) Getting Back on Track?Read the original story

    Apr 29, 2017 | Fox News

    Can these two drugs get Regeneron's shares back to their winning ways? Given these drugs target multibillion-dollar indications, I think the answer is yes. Dupixent inhibits interleukin-4 and interleukin-13, two anti-inflammatory proteins that can lead to eczema, a condition that causes itchy skin lesions and other symptoms that can take a big toll on patients' quality of life.

    Comment?

  14. UPDATE 2-Sanofi beats profit forecasts, upbeat on prospects for eczema drugRead the original story w/Photo

    Apr 28, 2017 | Reuters

    ... before discounts and rebates to insurers is far more expensive than topical medicines and steroids used to treat eczema, it is less expensive than other injectable antibody drugs for serious skin conditions, such as psoriasis, that list for about ...

    Comment?

  15. Novan Presents Preclinical Data From Inflammatory Skin Diseases ProgramRead the original story

    Apr 26, 2017 | BioSpace

    ... and dose-dependent inhibition of inflammation comparable to betamethasone, a mid-potency corticosteroid used to treat eczema patients. "Both psoriasis and atopic dermatitis patients are in need of new topical therapeutic options," said Alan Menter, ...

    Comment?

  16. Zai Lab Acquires China Rights To Novel Antibiotic From Paratek PharmaRead the original story

    Apr 24, 2017 | BioSpace

    ... n-licensed product: the company is developing four cancer candidates, two anti-inflammatory products, a treatment for eczema and now an antibiotic. Zai also recently partnered with GE Healthcare to build a biomanufacturing plant in Suzhou.

    Comment?

  17. Biotech exec finds success, sobriety after 2008 collapseRead the original story w/Photo

    Mar 31, 2017 | NewsOK.com

    ... including serving with Mike Centola as co-CEO of Haus Bioceuticals, which manufactures MetaDerm ointment to treat eczema and psoriasis, using natural herbs from India. Payne separated from Haus to focus on Ultra Botanica and the curcumin-rich ...

    Comment?

  18. FDA Approves First Drug for Moderate and Severe Eczema CasesRead the original story

    Apr 20, 2017 | American Society for Quality

    The Food and Drug Administration on Tuesday approved Dupixent for moderate or severe eczema, which causes red, fiercely itchy rashes on the face, arms and legs. In three studies of the drug including a total of 2,119 participants, one-third to two-thirds achieved clear or nearly clear skin after 16 weeks of treatment.

    Comment?

  19. Sanofi Genzyme hit with patent lawsuit over new eczema drugRead the original story

    Apr 20, 2017 | Business Journal

    ... a subsidiary of Amgen (Nasdaq: AMGN), filed a complaint in Los Angeles federal court on April 5 claiming that an eczema drug developed by Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals (Nasdaq: REGN) infringes a patent related to a failed asthma ...

    Comment?

  20. Lilly and Incyte's Loss Is AbbVie and Regeneron's GainRead the original story w/Photo

    Apr 17, 2017 | Fox News

    ... was concerns over manufacturing at one of Sanofi's facilities. Recently, the two companies won FDA approval for a new eczema drug, Dupixent, that's made at the same location, so it seems that the FDA's manufacturing concerns have been addressed. ...

    Comment?